Evidence map›Paper›PMID 39458697›Full record

ArticlePolymers2024

Towards Photocrosslinkable Lyotropic Blends of Organosolv Lignin and Hydroxypropyl Cellulose for 3D Printing by Direct Ink Writing.

Mehmet-Talha Yapa, Jacques Lalevée, Marie-Pierre Laborie

Abstract read
In one paragraph

Article in Polymers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mehmet-Talha YapaForest Biomaterials, Institute of Earth and Environmental Sciences, Faculty of Environment and Natural Resources, University of Freiburg, Werthmanstr. 6, 79085 Freiburg im Breisgau, Germany.ORCID 0009-0002-2107-7034
Jacques LalevéeUniversité de Haute Alsace, CNRS, IS2M UMR 7361, 68100 Mulhouse, France.ORCID 0000-0001-9297-0335
Marie-Pierre LaborieForest Biomaterials, Institute of Earth and Environmental Sciences, Faculty of Environment and Natural Resources, University of Freiburg, Werthmanstr. 6, 79085 Freiburg im Breisgau, Germany.

Funding

Federal Ministry of Education and Research Funding code 13XP5141 "AM Wood"
6 · The paper itself

Abstract

Polymer blends containing up to 70% organosolv lignin content and lyotropic cellulose derivatives have been established as "lignin inks" for direct ink writing of fully biobased 3D parts. However, a fast-crosslinking mechanism is needed to improve throughput and design space. In this paper, UV-photocrosslinkable organosolv lignin/hydroxypropyl cellulose inks are formulated through doping with common photocrosslinkers. The most potent photocrosslinkers for neat hydroxypropyl cellulose, lignin and their blends are determined through a series of DOEs. Hydroxypropyl cellulose is significantly more amenable to photocrosslinking than organosolv lignin. The optimal photocrosslinkable ink formulations are printable and exhibit up to 70% gel content, although thermal post-curing remains essential. Chemical, thermal, and mechanical investigations of the photocrosslinked 3D parts evidence efficient crosslinking of HPC through its hydroxyl groups, while lignin appears internally plasticized and/or degraded during inefficient photocrosslinking. Despite this, photocrosslinkable inks exhibit improved tensile properties, shape flexibility, and fidelity. The heterogeneous crosslinking and residual creep highlight the need to further activate lignin for homogeneous photocrosslinking in order to fully exploit the potential of lignin inks in DIW.

Indexed as

3D printingcationic initiationcellulose derivativesdirect ink writingligninphoto-crosslinkingradical initiationTaguchi designwood-based biopolymers

Identifiers

PMID39458697
PMCPMC11510783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.